Latest Headlines

Latest Headlines

Cardio3 dives into CAR-T with $180M Celdara deal

Cardio3 BioSciences is buying the cancer division of Celdara Medical, trading $10 million up front and promising more in exchange for a seat at the immuno-oncology table. 

Med tech exits pick up in 2014, momentum to continue into 2015

Venture-backed medical device and diagnostics companies are benefiting from a groundswell of investor interest in life sciences that has been spearheaded by great biotech returns for the last several years.

NPS is officially up for sale. Will deal-minded Shire bid?

After months of takeover speculation, New Jersey's NPS Pharmaceuticals is officially up for grabs. And now, all eyes are on rumored suitor Shire.

With Swiss pickup, Pfizer adds CMV candidate to growing vaccines unit

After 2014's growth spurt, Pfizer's vaccines unit is not done expanding. The pharma giant has grabbed privately held Swiss company Redvax for an undisclosed sum, adding a preclinical human cytomegalovirus (CMV) vaccine candidate and a tech platform and IP related to a second, undisclosed vaccine program.

Pfizer continues deal spree with Redvax CMV vaccine buyout

Pfizer has added an acquisition pact to its latest string of deals. The pharma giant said today that it is buying out Redvax, a subsidiary of Switzerland's Redbiotec, in order to get its hands on a preclinical cytomegalovirus (CMV) vaccine candidate.

Fujifilm deepens its CMO heft with Kalon buyout

Fujifilm has completed its acquisition of Kalon Biotherapeutics, a contract manufacturer with a focus on vaccines.

Lilly closes Novartis deal, creating second-largest animal health giant

Eli Lilly started the new year by announcing it has closed its $5.4 billion acquisition of Novartis Animal Health, in the process expanding its Elanco animal health unit to 17 manufacturing sites and 14 R&D centers.

Rumors that Stryker will buy Smith & Nephew pick up steam

Bloomberg reports that Stryker is planning to offer a premium for the U.K.'s S&N of about 30%. Currently, the target has a valuation of about $16.3 billion. The sources say a tax inversion is not planned. However, one of the unnamed sources also says Stryker's management could change its mind.

Will biopharma keep riding that mammoth M&A wave? Short answer's yes

It's been a wild ride through the M&A world for pharma this year, and analysts predict that may just continue into 2015. Companies have been wheeling and dealing at breakneck pace, with more than a couple inking multiple pacts. But plenty of drugmakers are still in search of a deal that will move the needle.

Merger mania remakes the landscape

2014 was the year for medical device M&A activity. We don't expect to see med tech merger mania slow anytime soon, as the underlying motivations to improve growth rates, save on taxes and buy into new technology haven't changed. But there just aren't very many big medical device companies and that in itself limits the deal potential going forward.